Menu Search
Equities

NanoViricides, Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
NV3P:MUN

NanoViricides, Inc

Actions
  • Price (EUR)0.81
  • Today's Change-0.01 / -1.22%
  • Shares traded600.00
  • 1 Year change-38.64%
  • Beta1.2998
Data delayed at least 15 minutes, as of Feb 13 2026 07:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

NanoViricides, Inc. is a clinical-stage company. The Company is engaged in developing a class of drugs that it calls nanoviricides, using a platform technology based on the application of nanomedicine technologies to the complex issues of viral diseases. Its lead drug candidate is NV-387, a broad-spectrum antiviral drug that has demonstrated activity in lethal lung infection animal model studies of Coronavirus (COVID), Respiratory Syncytial Virus, Influenza, Orthopoxvirus model for Smallpox and MPox, and even in a humanized mice model for Measles. It is focused on advancing Phase II clinical trials. Its other advanced drug candidate is NV-HHV-1 for the treatment of Shingles rash. Its NV-CoV-2 and NV-CoV-2-R are drug candidates for the treatment of COVID. Its portfolio also includes NV-HIV-1, a novel mechanism Anti-HIV Drug Candidate. Its other drug candidates include treatment for viral infections, including Dengue viruses, Ebola viruses, among others.

  • Revenue in USD (TTM)0.00
  • Net income in USD-8.13m
  • Incorporated2023
  • Employees7.00
  • Location
    NanoViricides, Inc1 Controls DriveSHELTON 06484United StatesUSA
  • Phone+1 (203) 937-6137
  • Fax+1 (302) 655-5049
  • Websitehttps://www.nanoviricides.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.